PERGOVERIS IN CONTROLLED OVARIAN STIMULATION IN ASSISTED REPRODUCTIVE TECHNOLOGY PROGRAMMS
A study was conducted to study the experience of using the drug Pergoveris during a controlled ovarian stimulation (COS) in assisted reproductive technology (ART) The results showed that the addition lyuteiniziruschego hormone (especially recombinant) COS protocols do not provide any benefits in patients with normal ovarian reserve under the age of 38 years. There was a significant decrease in the number of oocytes obtained when using products containing luteinizing hormone, so should not be used in the urinary gonadotropins of ART cycles in which the paneer conduct preimplantation genetic diagnosis. drug use Pergoveris shown encouraging results during the COS in women older than 37y.o., especially in the age group over 40.